[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text]

DEA Expands Cannabis Research! Ho, Ho, Hold up!

[/fusion_text][/fusion_builder_column][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]What a way to say Merry Christmas, feds! This Wednesday, the DEA relaxed regulations on cannabis concentrate research. Effective immediately, current authorized cannabidiol researchers can modify protocols and continue their research seamlessly.

Until this policy adjustment, researchers approved for a certain amount of CBD were required to submit their changes in writing, for approval, before continuing research. These hangups delay further understanding of cannabis’ capabilities when by the day, we learn new therapy applications. 

Look towards Israel, the epicenter of current cannabis research, to witness CBD treatment as standard protocol in hospitals.

The new year is looking good for cannabis! Stay tuned and stay lifted as we keep you updated on cannabis news.[/fusion_text][fusion_text]

Drug policy reformers have been urging the U.S. government to ease restrictions on scientific research into marijuana’s potential as medicine, saying the federal government’s strict rules had prevented needed studies… A handful of companies are developing cannabis-derived drugs. Pioneering the effort is Britain’s GW Pharmaceuticals, which is slated next year to deliver the results of four late-stage U.S. studies of its botanical pot-based epilepsy treatment. INSYS Therapeutics Inc and Zynerba Pharmaceuticals Inc are working on much earlier stages of development with synthetic cannabis for a number of disorders.

source: reuters[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]